Secondary Schizophrenia (174 page)

replication of,
171–
2

neuronal storage disorders that

withdrawal,
121

synaptic pruning,
312

present with psychosis in

diagnosis, criteria for,
116–
19

adulthood,
215t

clinical description,
116

syphilis,
394

Niemann-Pick Disease type C,
217,

common neural substrate,

systemic lupus erythematosus (SLE),

217f
,
218,
220–
2

118–
19

398

TACTICS MDs USE,
10t

histamine H2 receptor,
182

incidence of TBI,
186

tactile exam,
52

opioids/nonsteroidal anti-

secondary auditory hallucinations

inflammatory drugs,
182

in,
30–
1

tactile hallucinations,
266

epidemiology,
180

trifluoperazine,
87

tardivelike dyskinesia (TD),
51,
395

future research,
183

general etiological factor,
180–
1

trigeminal/facial corneal reflex,
49

Tatetsu, S.,
128

general risk factors,
180

Trimble, M. R.,
105

Tay Sach’s Disease (TSD),
215t
,
216

implications for clinical practice,

183

trinucleotide repeat disorders,
352t

Teggin, A. F.,
32

management,
183

Tucker, G. J.,
382

Tellenbach, H.,
104

pathogenesis of drug-induced,
183

Turner Syndrome,
313

temporal association, in SZ,
9,
17

secondary tactile hallucinations,
34

secondary visual hallucinations,

TXB1,
319

temporal lobectomy,
31,
33

25–
6

temporal lobe epilepsy (TLE),
80,
394

summary/conclusions,
183

ubiquitin fusion degradation I gene,

treatment,
396–
7

319

temporomandibular joint dysfunction,

29

toxoplasmosis,
281

Ueda, Y.,
236

tertiary syphilis,
394

tramadol,
370

UFD1L,
319

tetrahydrocannabinol (THC),
169,

transcranial magnetic stimulation

Ujike, H.,
134

173,
174

(TMS),
133

Umbricht, D.,
84

δ
-9-tetrahydrocannabinol,
114

transient tinnitus,
29

uncinate fits,
32–
3

tetrathiomolybdate,
340

transmission disequilibrium test

unilateral tinnutus,
29

thalamo-cortical dissociations,
66

(TDT),
291

uniparental disomy (UPD),
328,

thalamus,
183

traumatic brain injury (TBI),

329–
30

association with

thioridazine,
87

schizophrenia-like

US Drug Abuse Warning Network

Thomeer, E. C.,
234

psychosis (SLP)

(DAWN),
142

tinnitus,
28–
9

clinical presentation,
190–
3

US National Epidemiological

pulsatile,
29

age of TBI,
190,
193

Catchment Area study,
187

transient,
29

birth trauma and schizophrenia,

Utena, H.,
130

unilateral,
29

193

course,
191

Todd’s paralysis,
84

diagnostic criteria,
191

Val allele,
317–
18

Tomiyama, C.,
130

head injury characteristics,
190–
1

valproic acid,
250,
353,
399

psychopathology,
191

Toone, B. K.,
83,
84

relationship with epilepsy,
192–
3

Van Os, J.,
22,
171,
173

topiramate,
87

risk factors and pathophysiology,

varying movement disorder,
218

Tourette’s Syndrome,
396

191–
2

vascular dementia (VaD),
200–
1

pre-existing vulnerability,
192

toxic psychosis (delirium),
120

specific neuroanatomical

Veith, G.,
94

in amphetamine abusers,
130

substrates,
191–
2

velocardiofacial syndrome (VCFS),
53

clinical features,
179–
80

specific underlying cognitive

facial features, typical,
310,
311f

delirium/dementia/psychosis

syndrome,
192

features warrant testing in

characteristics,
181t

sex differences,
190

schizophrenia patient,
310t

DSM-IV diagnostic criteria for

conclusions,
193

FISH test,
310,
311f
,
313

delirium,
179–
80

epidemiology,
186–
90, 190t

ideogram of chromosome 22,
317f

commonly used drugs as cause,
181,

case control studies,
187–
9

molecular genetics related to

183

risk factors for schizophrenia

chromosome 22q,
316–
19

antibiotics,
182–
3

following TBI,
189

COMT,
317–
18

anticholinergics,
181–
2

studies examining association

PRODH,
318

anticonvulsants,
182

strength,
187–
9

mouse models,
318

antidepressants,
182

case reports,
186–
7

TXB1,
319

antiemetics,
182

cohort studies,
189–
90

UFD1L,
319

antiparkinsonians,
182

cross-sectional surveys,
187

ZDHHC8,
318–
19

antipsychotics,
182

future directions,
193–
4

mouse models of VCFS,
319–
20

benzodiazepines,
182

implications for medicolegal

prepulse inhibition,
319–
20

corticosteroids,
182

practice,
193–
4

sensorimotor gating,
320

velocardiofacial syndrome (cont.)

irritative,
372

future research,
343–
4

neurodevelopmental hypothesis of

palinopsia,
370

mechanisms for psychosis,

schizophrenia,
312–
13

photopsias,
370

343

abnormalities prior to onset,
312

release,
372

research agenda,
343–
4

structural brain abnormalities at

trigger factors in,
370

in general,
337,
338

onset,
312

visual auras,
370

neurological features,
341

overview of,
309–
11

visual word form area (VWFA),

pathology of,
338

premorbid neuropsychological and

373

pathophysiology of,
338

brain morphometric

psychiatric features,
341

findings,
313–
15

vitamin E,
335

psychotic features,
340–
1

psychiatric diagnoses in

Vogels, A.,
329

treatment for psychosis,
341–
3

childhood,
313–
14

problems with,
342–
3

psychological abnormalities in

volumetric intercorrelations,
63,
66

psychotropics,
341–
2

child,
313

von Meduna, L.,
103

treatment for WD,
339–
40

quantitative MRI studies in child,

voxel-based morphometry (VBM),
6,

Wimmer, A.,
381

314–
15

6f
,
6

structural brain abnormalities,

Winder, R.,
64

314

Wisconsin Card Sorting Test,
349

prevalence in schizophrenia,
313

Walterfang, M.,
267

quantitative MRI studies in adults,

withdrawal,
27–
8,
35,
121

Wechsler Memory Scale,
207

315–
16

Witton, J.,
120

schizophrenia phenotype,
315

Weinberger, D. R.,
7

Wolf, P.,
87,
104,
105

schizophrenia risk for person with,

Weinberger, L. M.,
374

311–
12

Wolfram Disease,
236

treatment of VCFS-associated

Weiser, M.,
120

working memory

psychiatric illnesses,
316

Wernicke’s area,
30

fMRI study,
5

ventral stream,
25

Wernicke’s Syndrome, alcohol-related,

ketamine effect on,
146

Ventral Tegmental Area (VTA),
106,

53

Wortis, J.,
60

107,
118,
119

West, C.,
24

ventricular volume increases,
6

Westphal variant, of Huntington’s

xanthomas,
218,
248–
9

Verdoux, H.,
173

Disease,
349

xenon inhalation method,
61

Verhoeven, W. M.,
329

Whitman, B. Y.,
329

Xiao, J.,
198

very long chain fatty acids (VLCFA),

WHO schizophrenia study,
175

243,
244

Wicker, B.,
373

Yamazaki, M.,
233

vigabatrin,
87

Wilcox, J. A.,
187,
193

Younger, J.,
329

violence risk, in substance-induced

Wilson’s Disease (WD)

Yui, K.,
128,
131,
133,
134

psychosis,
122

antipsychotics for,
399

visual auras,
370

ATP7B gene,
337,
338

basal ganglia role in,
359

Zammit, S.,
171

visual exam, for schizophrenia,
51